Nigel ACA - ICON PLC Chief Officer
| ICLR Stock | USD 212.84 0.69 0.33% |
Executive
Nigel ACA is Chief Officer of ICON PLC
| Age | 50 |
| Address | South County Business Park, Dublin, Ireland, D18 X5R3 |
| Phone | 353 1 291 2000 |
| Web | https://www.iconplc.com |
ICON PLC Management Efficiency
The company has return on total asset (ROA) of 0.0417 % which means that it generated a profit of $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0799 %, meaning that it created $0.0799 on every $100 dollars invested by stockholders. ICON PLC's management efficiency ratios could be used to measure how well ICON PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Equity is likely to grow to 0.11, while Return On Tangible Assets are likely to drop 0.1. At this time, ICON PLC's Debt To Assets are relatively stable compared to the past year. As of 11/28/2024, Fixed Asset Turnover is likely to grow to 17.00, though Net Tangible Assets are likely to grow to (4.1 B).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| JD Esq | Caribou Biosciences | 69 | |
| Ram Kamineni | Krystal Biotech | N/A | |
| Robin Andrulevich | Sana Biotechnology | 58 | |
| Amy CFA | Caribou Biosciences | N/A | |
| George Lloyd | Royalty Pharma Plc | 64 | |
| Caroline MD | Ikena Oncology | 52 | |
| Alexander Constan | Ikena Oncology | N/A | |
| Sandy Balkin | Royalty Pharma Plc | N/A | |
| Sara Klymkowsky | Royalty Pharma Plc | N/A | |
| James Reddoch | Royalty Pharma Plc | 54 | |
| Christine Wilson | Krystal Biotech | N/A | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| John MD | Sana Biotechnology | N/A | |
| Gary MD | Sana Biotechnology | N/A | |
| Marshall MD | Royalty Pharma Plc | 48 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Timothy MBA | Caribou Biosciences | 55 | |
| Meg Dodge | Krystal Biotech | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Jennifer Robinson | Verve Therapeutics | N/A | |
Management Performance
| Return On Equity | 0.0799 | ||||
| Return On Asset | 0.0417 |
ICON PLC Leadership Team
Elected by the shareholders, the ICON PLC's board of directors comprises two types of representatives: ICON PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICON. The board's role is to monitor ICON PLC's management team and ensure that shareholders' interests are well served. ICON PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICON PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brendan Brennan, CFO and Member of Executive Committee | ||
| Nigel ACA, Chief Officer | ||
| Dr MBA, CEO Director | ||
| Jonathan Curtain, Senior Finance | ||
| Niamh Murphy, Director Communications | ||
| Joe Cronin, Chief Officer | ||
| Simon Holmes, President Partnerships | ||
| Jonathan ACA, Senior Finance | ||
| Diarmaid Cunningham, Executive Vice President General Counsel, Secretary | ||
| Dana Snr, Ex Management | ||
| Nigel Clerkin, Chief Officer | ||
| David Green, Vice Marketing | ||
| Gary Curtis, Senior Pharmacology | ||
| John Climax, Co-Founder, Non Executive Director and Vice Chairman of Quality Committee | ||
| Peter Schueler, Senior CNS | ||
| Thomas OLeary, Chief Officer |
ICON Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICON PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0799 | ||||
| Return On Asset | 0.0417 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 20.4 B | ||||
| Shares Outstanding | 82.56 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 99.35 % | ||||
| Number Of Shares Shorted | 1.28 M | ||||
| Price To Earning | 33.93 X |
Pair Trading with ICON PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ICON PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ICON PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with ICON Stock
Moving against ICON Stock
| 0.83 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.83 | GILD | Gilead Sciences | PairCorr |
| 0.8 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.75 | ESPR | Esperion Therapeutics | PairCorr |
| 0.55 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to ICON PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ICON PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ICON PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ICON PLC to buy it.
The correlation of ICON PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ICON PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ICON PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ICON PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ICON Stock Analysis
When running ICON PLC's price analysis, check to measure ICON PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ICON PLC is operating at the current time. Most of ICON PLC's value examination focuses on studying past and present price action to predict the probability of ICON PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ICON PLC's price. Additionally, you may evaluate how the addition of ICON PLC to your portfolios can decrease your overall portfolio volatility.